Streetwise Reports Examines Analyst’s View of ‘One of the Most Undervalued Biotech Companies in Canada’

SAN FRANCISCO, Dec. 07, 2017 (GLOBE NEWSWIRE) — David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm.

Included in this article is: Resverlogix Corp. (RVX:TSX) 

In a Nov. 15, 2017, research report, Beacon Securities Ltd. analyst David Kideckel described Resverlogix Corp. as a company with “a game-changing medical technology platform and drug development platform,” and “a deeply talented senior management team.” He stated, “We believe that Resverlogix is one of the most undervalued and most impressive biotechnology companies listed on the Toronto Stock Exchange. . .[it] has flown under the radar of ‘healthcare and biotechnology-focused’ investment banks, which is unfortunate (or fortunate for future investors), given the company’s blockbuster market potential.”

Resverlogix’s epigenetics drug development platform is based on targeting bromodomain and extra-terminal (BET) proteins, and its lead drug candidate, apabetalone (RVX-208), is one such inhibitor. With its platform, the company is addressing epigenetics and BET inhibition, which, wrote Kideckel, “are among the hottest fields in the global biotechnology sector with significant upside potential.”

Three clinical trials are underway involving apabetalone. The first is a Phase 3 study (BETonMACE) for the secondary prevention of major adverse cardiovascular events (MACE) in high-risk patients with diabetes. The second is a Phase 2 study in chronic kidney disease, and the third is a Phase 2 trial in Fabry Disease (a rare disease).

Continue reading this article: Coverage Initiated on ‘One of the Most Undervalued Biotech Companies in Canada’ 

About Streetwise Reports – The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Resverlogix Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. 

Please see the end of the article for the complete disclosures: Coverage Initiated on ‘One of the Most Undervalued Biotech Companies in Canada’

CONTACT: Contact Information: 
Carrie Beal Amaro 
Publisher 
cbealamaro@streetwisereports.com

Left Menu Icon
Right Menu Icon